GlassScriptPhysician profile
Chung The Bui
NPI 1427143072
$17,909.59
in general payments reported to CMS, 2019-2025
37 companies · $1,458 in 2025
The $1,458 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,941 · 2020: $917 · 2021: $2,062 · 2022: $2,821 · 2023: $2,492 · 2024: $3,218 · 2025: $1,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,868 · Consulting Fee: $175 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,868.48 |
| Consulting Fee | $175.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $124.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,685.36 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,286.10 | 2019-2025 | Jardiance |
| Amgen INC. | $2,029.09 | 2019-2025 | Evenity, Prolia, Prolia |
| Gilead Sciences, INC. | $1,177.17 | 2019-2024 | Vemlidy |
| Lilly USA, LLC | $1,093.99 | 2019-2025 | Jardiance, Mounjaro |
| Janssen Pharmaceuticals, INC | $1,025.70 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $972.42 | 2020-2023 | |
| Amarin Pharma, INC. | $752.34 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $496.04 | 2024-2025 | Voquezna |
| Abbvie INC. | $477.79 | 2019-2024 | Linzess, Creon |
| Allergan, INC. | $425.06 | 2019 | |
| Novartis Pharmaceuticals Corporation | $363.41 | 2019 | |
| Aimmune Therapeutics, INC. | $298.72 | 2024-2025 | Zenpep |
| Novo Nordisk INC | $247.50 | 2021-2023 | |
| Otsuka America Pharmaceutical, INC. | $237.91 | 2022-2024 | Rexulti |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chung Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.